These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32313723)

  • 1. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
    Liu J; Li C; Seery S; Yu J; Meng X
    Oncoimmunology; 2020; 9(1):1746112. PubMed ID: 32313723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.
    Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T
    Front Immunol; 2024; 15():1375136. PubMed ID: 39072325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Kim R; Keam B; Hahn S; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Sep; 20(5):331-338.e4. PubMed ID: 31164319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
    O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
    Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
    J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
    Liu W; Huo G; Chen P
    BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.
    Chen W; Chen J; Zhang L; Cheng S; Yu J
    BMC Cancer; 2023 Aug; 23(1):791. PubMed ID: 37612622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.